Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
Related Articles
Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital
MarketScreener: Anumana, Inc. announced that it has received a round of funding from new investor, Boston Scientific Corporation on April 24, 2025. The transaction included participation from returning investors, Matrix…April 24, 2025
Mayo Clinic launches 2 companies in support of new health analytics platform initiative
Becker's Hospital Review: Rochester, Minn.-based Mayo Clinic launched two new companies to support its newly developed Remote Diagnostics and Management Platform, which connects data with artificial intelligence technologies for clinical…April 13, 2021
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022